Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Luye Pharma Group ( (HK:2186) ) has shared an update.
Luye Pharma Group has completed the issuance of 1,500,000 Exchangeable Preference Shares through its wholly-owned subsidiary, Luye Geneora Holding Limited. These shares are exchangeable into existing shares of Boan Biotech, representing approximately 16.15% of Boan Biotech’s issued shares. This strategic financial move, involving investment from Bluebell Asset Holding Ltd., aims to strengthen Luye Pharma’s position in the biotech sector without diluting Boan Biotech’s current shareholding structure.
The most recent analyst rating on (HK:2186) stock is a Hold with a HK$3.50 price target. To see the full list of analyst forecasts on Luye Pharma Group stock, see the HK:2186 Stock Forecast page.
More about Luye Pharma Group
Luye Pharma Group is a pharmaceutical company involved in the healthcare industry, focusing on the development and production of innovative drugs and therapies. The company operates globally, with a strong emphasis on the Asian market, and is known for its commitment to advancing healthcare solutions.
Average Trading Volume: 27,894,002
Technical Sentiment Signal: Strong Sell
Current Market Cap: HK$11.63B
See more data about 2186 stock on TipRanks’ Stock Analysis page.